Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Obesity (Silver Spring) ; 15(11): 2664-72, 2007 Nov.
Article in English | MEDLINE | ID: mdl-18070757

ABSTRACT

OBJECTIVE: To investigate the involvement of hypoadiponectinemia and inflammation in coupling obesity to insulin resistance in melanocortin-3 receptor and melanocortin-4 receptor knockout (KO) mice (Mc3/4rKO). RESEARCH METHODS AND PROCEDURES: Sera and tissue were collected from 6-month-old Mc3rKO, Mc4rKO, and wild-type C57BL6J litter mates maintained on low-fat diet or exposed to high-fat diet (HFD) for 1 or 3 months. Inflammation was assessed by both real-time polymerase chain reaction analysis of macrophage-specific gene expression and immunohistochemistry. RESULTS: Mc4rKO exhibited hypoadiponectinemia, exacerbated by HFD and obesity, previously reported in murine models of obesity. Mc4r deficiency was also associated with high levels of macrophage infiltration of adipose tissue, again exacerbated by HFD. In contrast, Mc3rKO exhibited normal serum adiponectin levels, irrespective of diet or obesity, and a delayed inflammatory response to HFD relative to Mc4rKO. DISCUSSION: Our findings suggest that severe insulin resistance of Mc4rKO fed a HFD, as reported in other models of obesity such as leptin-deficient (Lep(ob)/Lep(ob)) and KK-A(y) mice, is linked to reduced serum adiponectin and high levels of inflammation in adipose tissue. Conversely, maintenance of normal serum adiponectin may be a factor in the relatively mild insulin-resistant phenotype of severely obese Mc3rKO. Mc3rKO are, thus, a unique mouse model where obesity is not associated with reduced serum adiponectin levels. A delay in macrophage infiltration of adipose tissue of Mc3rKO during exposure to HFD may also be a factor contributing to the mild insulin resistance in this model.


Subject(s)
Adiponectin/metabolism , Inflammation/metabolism , Insulin Resistance/physiology , Obesity/metabolism , Receptor, Melanocortin, Type 3/metabolism , Receptor, Melanocortin, Type 4/metabolism , Adipocytes/drug effects , Adipocytes/metabolism , Adipocytes/pathology , Animals , Body Composition/drug effects , Body Composition/physiology , Dietary Fats/pharmacology , Disease Models, Animal , Humans , Inflammation/pathology , Inflammation/physiopathology , Leptin/blood , Male , Mice , Mice, Knockout , Obesity/pathology , Obesity/physiopathology , Receptor, Melanocortin, Type 3/genetics , Receptor, Melanocortin, Type 4/genetics
2.
J Clin Endocrinol Metab ; 90(12): 6650-6, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16204368

ABSTRACT

INTRODUCTION: Mitochondrial biogenesis is a complex process, and several factors and signaling pathways regulate this process in muscle or brown adipocytes. The aim of the study was to explore pathways affecting mitochondrial biogenesis and fatty acid oxidation (FAO) in human white adipocytes. METHODS: Human preadipocytes obtained from liposuction samples were differentiated in vitro. On the 10th day of differentiation, 4 microM forskolin and 1 microM peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist (pioglitazone, rosiglitazone, or GW 929) or 10 microM PPARalpha agonist (WY-14,643) were added to the media for 96 h. Quantitative real-time PCR was used to determine gene expression/mitochondrial copy number and 14C-labeled palmitate to measure direct energy dissipation. RESULTS: The treatment of adipocytes with forskolin increased mitochondrial copy number and the expression of genes involved in mitochondrial biogenesis (PPARgamma coactivator 1alpha and transcriptional factor A) and fatty acid oxidation (PPARalpha and medium-chain acyl-coenzyme A dehydrogenase). The end (CO2) and intermediate products (14C-labeled acid-soluble products) of FAO were also increased after forskolin treatment. PPARgamma and PPARalpha agonists increased mitochondrial copy number, uncoupling protein 1, medium-chain acyl-coenzyme A dehydrogenase, and carnitine palmitoyltransferase 1, but did not change PPARalpha, PPARgamma coactivator 1alpha, or transcriptional factor A mRNA levels. FAO was higher after rosiglitazone, GW 929, and WY-14,643 but not after pioglitazone treatment. CONCLUSIONS: Pharmacological activation of the cAMP or PPARgamma pathway pushes the white adipocyte down the oxidative continuum. The direct energy-dissipating effects could be significant tools to treat obesity and to improve insulin resistance in type 2 diabetic patients by reduction of fat accumulation in adipocytes or by reprogramming fatty acid metabolism.


Subject(s)
Adipocytes/physiology , Adipocytes/ultrastructure , Mitochondria/physiology , Mitochondria/ultrastructure , Adipocytes/drug effects , Cells, Cultured , Colforsin/pharmacology , DNA, Mitochondrial , Fatty Acids/metabolism , Gene Dosage/drug effects , Gene Expression , Glycerol/metabolism , Humans , Mitochondria/drug effects , Osmolar Concentration , Oxidation-Reduction , PPAR alpha/agonists , PPAR gamma/agonists , PPAR gamma/antagonists & inhibitors
3.
J Clin Invest ; 115(7): 1934-41, 2005 Jul.
Article in English | MEDLINE | ID: mdl-16007256

ABSTRACT

Metabolic flexibility of skeletal muscle, that is, the preference for fat oxidation (FOx) during fasting and for carbohydrate oxidation in response to insulin, is decreased during insulin resistance. The aim of this study was to test the hypothesis that the capacity of myotubes to oxidize fat in vitro reflects the donor's metabolic characteristics. Insulin sensitivity (IS) and metabolic flexibility of 16 healthy, young male subjects was determined by euglycemic hyperinsulinemic clamp. Muscle samples were obtained from vastus lateralis, cultured, and differentiated into myotubes. In human myotubes in vitro, we measured suppressibility (glucose suppression of FOx) and adaptability (an increase in FOx in the presence of high palmitate concentration). We termed these dynamic changes in FOx metabolic switching. In vivo, metabolic flexibility was positively correlated with IS and maximal oxygen uptake and inversely correlated with percent body fat. In vitro suppressibility was inversely correlated with IS and metabolic flexibility and positively correlated with body fat and fasting FFA levels. Adaptability was negatively associated with percent body fat and fasting insulin and positively correlated with IS and metabolic flexibility. The interindividual variability in metabolic phenotypes was preserved in human myotubes separated from their neuroendocrine environment, which supports the hypothesis that metabolic switching is an intrinsic property of skeletal muscle.


Subject(s)
Dietary Fats/metabolism , Muscle Fibers, Skeletal/metabolism , Adolescent , Adult , Glucose/metabolism , Glucose Clamp Technique , Humans , In Vitro Techniques , Insulin Resistance , Male , Models, Biological , Oxidation-Reduction , Palmitic Acid/metabolism , Phenotype
4.
Obes Res ; 11(1): 65-74, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12529487

ABSTRACT

OBJECTIVE: To validate the human mesenchymal stem cells (hMSCs) as a new in vitro model for the study of human adipogenesis, to develop the optimal protocol for the differentiation of hMSCs into adipocytes, and to describe effect of mitogen-activated protein kinase on hMSC differentiation into adipocytes. RESEARCH METHODS AND PROCEDURES: hMSCs, obtained commercially, were differentiated by exposure to insulin, dexamethasone, indomethacin, and 3-isobutyl-1-methylxanthine three times for 3 days each. Various differentiation conditions were examined to optimize differentiation as measured by Oil Red O staining. The gene expression during adipogenic conversion was assessed by reverse-transcription polymerase chain reaction, real-time reverse-transcription polymerase chain reaction, and Western blotting. RESULTS: hMSCs differentiated into adipocytes to a different extent depending on the experimental conditions. We have found that differentiation medium based on medium 199 and containing 170 nM insulin, 0.5 mM 3-isobutyl-1-methylxanthine, 0.2 mM indomethacin, 1 microM dexamethasone, and 5% fetal bovine serum was optimal. However, the replacement of fetal bovine serum with rabbit serum (15%) led to further enhancement of differentiation. Inhibition of mitogen-activated protein kinase activation also facilitated adipogenic conversion of hMSCs. The pattern of genes expressed during hMSC differentiation into adipocytes (adipsin, peroxisome proliferator-activated receptor-gamma, CCAAT/enhancer-binding protein-beta, GLUT4, and leptin) was similar to that observed in other in vitro adipocyte models. DISCUSSION: hMSCs are renewable sources of noncommitted precursors that are able to differentiate into mature adipocytes under the proper hormonal and pharmacological stimuli. Thus, hMSCs represent a new model for the study of human adipogenesis.


Subject(s)
Adipocytes/cytology , Mesoderm/cytology , Stem Cells/cytology , 1-Methyl-3-isobutylxanthine/pharmacology , Animals , Blood , Blotting, Western , Cell Differentiation/drug effects , Cells, Cultured , Clone Cells/cytology , Culture Media , Cyclin D1/genetics , Dexamethasone/pharmacology , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Glucocorticoids/pharmacology , Glucose/pharmacology , Humans , Indomethacin/pharmacology , Insulin/pharmacology , Mitogen-Activated Protein Kinase 1/antagonists & inhibitors , Mitogen-Activated Protein Kinase 3 , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Mitogen-Activated Protein Kinases/metabolism , Proliferating Cell Nuclear Antigen/genetics , RNA, Messenger/analysis , Rabbits , Reverse Transcriptase Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...